Pre-existing cardiovascular disease rather than cardiovascular risk factors drives mortality in COVID-19.


Journal

BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539

Informations de publication

Date de publication:
03 07 2021
Historique:
received: 07 03 2021
accepted: 24 06 2021
entrez: 4 7 2021
pubmed: 5 7 2021
medline: 13 7 2021
Statut: epublish

Résumé

The relative association between cardiovascular (CV) risk factors, such as diabetes and hypertension, established CV disease (CVD), and susceptibility to CV complications or mortality in COVID-19 remains unclear. We conducted a cohort study of consecutive adults hospitalised for severe COVID-19 between 1st March and 30th June 2020. Pre-existing CVD, CV risk factors and associations with mortality and CV complications were ascertained. Among 1721 patients (median age 71 years, 57% male), 349 (20.3%) had pre-existing CVD (CVD), 888 (51.6%) had CV risk factors without CVD (RF-CVD), 484 (28.1%) had neither. Patients with CVD were older with a higher burden of non-CV comorbidities. During follow-up, 438 (25.5%) patients died: 37% with CVD, 25.7% with RF-CVD and 16.5% with neither. CVD was independently associated with in-hospital mortality among patients < 70 years of age (adjusted HR 2.43 [95% CI 1.16-5.07]), but not in those ≥ 70 years (aHR 1.14 [95% CI 0.77-1.69]). RF-CVD were not independently associated with mortality in either age group (< 70 y aHR 1.21 [95% CI 0.72-2.01], ≥ 70 y aHR 1.07 [95% CI 0.76-1.52]). Most CV complications occurred in patients with CVD (66%) versus RF-CVD (17%) or neither (11%; p < 0.001). 213 [12.4%] patients developed venous thromboembolism (VTE). CVD was not an independent predictor of VTE. In patients hospitalised with COVID-19, pre-existing established CVD appears to be a more important contributor to mortality than CV risk factors in the absence of CVD. CVD-related hazard may be mediated, in part, by new CV complications. Optimal care and vigilance for destabilised CVD are essential in this patient group. Trial registration n/a.

Sections du résumé

BACKGROUND
The relative association between cardiovascular (CV) risk factors, such as diabetes and hypertension, established CV disease (CVD), and susceptibility to CV complications or mortality in COVID-19 remains unclear.
METHODS
We conducted a cohort study of consecutive adults hospitalised for severe COVID-19 between 1st March and 30th June 2020. Pre-existing CVD, CV risk factors and associations with mortality and CV complications were ascertained.
RESULTS
Among 1721 patients (median age 71 years, 57% male), 349 (20.3%) had pre-existing CVD (CVD), 888 (51.6%) had CV risk factors without CVD (RF-CVD), 484 (28.1%) had neither. Patients with CVD were older with a higher burden of non-CV comorbidities. During follow-up, 438 (25.5%) patients died: 37% with CVD, 25.7% with RF-CVD and 16.5% with neither. CVD was independently associated with in-hospital mortality among patients < 70 years of age (adjusted HR 2.43 [95% CI 1.16-5.07]), but not in those ≥ 70 years (aHR 1.14 [95% CI 0.77-1.69]). RF-CVD were not independently associated with mortality in either age group (< 70 y aHR 1.21 [95% CI 0.72-2.01], ≥ 70 y aHR 1.07 [95% CI 0.76-1.52]). Most CV complications occurred in patients with CVD (66%) versus RF-CVD (17%) or neither (11%; p < 0.001). 213 [12.4%] patients developed venous thromboembolism (VTE). CVD was not an independent predictor of VTE.
CONCLUSIONS
In patients hospitalised with COVID-19, pre-existing established CVD appears to be a more important contributor to mortality than CV risk factors in the absence of CVD. CVD-related hazard may be mediated, in part, by new CV complications. Optimal care and vigilance for destabilised CVD are essential in this patient group. Trial registration n/a.

Identifiants

pubmed: 34217220
doi: 10.1186/s12872-021-02137-9
pii: 10.1186/s12872-021-02137-9
pmc: PMC8254437
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

327

Subventions

Organisme : Medical Research Council
ID : MR/R016372/1
Pays : United Kingdom
Organisme : NIHR BRC South London &amp; Maudsley
ID : IS-BRC-1215-20018
Organisme : HDRUK
ID : HDRUK MR/S00310X/1.
Organisme : King's College London
ID : Prize Fellowship
Organisme : Medical Research Council
ID : MC_PC_17214
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_20058
Pays : United Kingdom
Organisme : NIHR BRC GSTT
ID : IS-BRC-1215-20006
Organisme : British Heart Foundation
ID : CH/1999001/11735 and RE/18/2/34213
Pays : United Kingdom
Organisme : Alzheimer's Society
ID : 171
Pays : United Kingdom

Références

Thorax. 2021 Apr;76(4):412-420
pubmed: 33408195
EClinicalMedicine. 2020 Nov;28:100574
pubmed: 33052324
PLoS One. 2019 Nov 25;14(11):e0225625
pubmed: 31765395
J Cardiovasc Electrophysiol. 2020 Dec;31(12):3077-3085
pubmed: 33017083
Circulation. 2018 Nov 13;138(20):e618-e651
pubmed: 30571511
Cancer Treat Res. 1995;75:95-112
pubmed: 7640169
Ann Intern Med. 2020 Aug 18;173(4):268-277
pubmed: 32374815
Artif Intell Med. 2021 Jul;117:102083
pubmed: 34127232
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
Arterioscler Thromb Vasc Biol. 2020 Aug;40(8):1818-1829
pubmed: 32510978
Eur Respir J. 2020 May 14;55(5):
pubmed: 32217650
Eur Heart J Cardiovasc Imaging. 2020 Jul 1;21(7):709-714
pubmed: 32391912
J Am Coll Cardiol. 2020 Aug 4;76(5):533-546
pubmed: 32517963
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
JAMA Cardiol. 2020 Jul 1;5(7):811-818
pubmed: 32219356
Heart. 2020 Dec 17;:
pubmed: 33334863
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Eur Heart J. 2017 Sep 21;38(36):2739-2791
pubmed: 28886619
J Am Coll Cardiol. 2021 Jan 26;77(3):314-325
pubmed: 33478655
Eur Heart J. 2015 Nov 7;36(42):2921-2964
pubmed: 26320112
Eur Heart J. 2020 Jun 7;41(22):2130
pubmed: 32227076
Eur Heart J. 2020 Sep 1;41(32):3038-3044
pubmed: 32882706
Diabetes Care. 2018 Mar;41(3):513-521
pubmed: 29330152
Diabetes Care. 2018 Oct;41(10):2127-2135
pubmed: 30104296
Stat Med. 1999 Mar 30;18(6):681-94
pubmed: 10204197
BMC Med Inform Decis Mak. 2018 Jun 25;18(1):47
pubmed: 29941004
JAMA. 2020 Jun 23;323(24):2518-2520
pubmed: 32437497
Cardiovasc Pathol. 2021 Jan - Feb;50:107300
pubmed: 33132119
Eur Heart J. 2020 May 14;41(19):1821-1829
pubmed: 32383763
Lancet Diabetes Endocrinol. 2020 Oct;8(10):813-822
pubmed: 32798472
Eur J Heart Fail. 2020 Jun;22(6):967-974
pubmed: 32485082
Int J Infect Dis. 2020 May;94:91-95
pubmed: 32173574
Eur Heart J. 2015 Nov 21;36(44):3075-3128
pubmed: 26320109
Eur Heart J. 2013 Sep;34(33):2636-48, 2648a-2648d
pubmed: 23824828
Rev Esp Cardiol (Engl Ed). 2020 Aug;73(8):669-672
pubmed: 32499016
BMJ. 2020 May 22;369:m1985
pubmed: 32444460
Lancet Diabetes Endocrinol. 2020 Oct;8(10):823-833
pubmed: 32798471
BMJ. 2013 May 20;346:f2350
pubmed: 23692896

Auteurs

Kevin O'Gallagher (K)

Department of Cardiology, King's College London British Heart Foundation Centre of Research Excellence, School of Cardiovascular Medicine and Sciences, London, UK.

Anthony Shek (A)

Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

Daniel M Bean (DM)

Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

Rebecca Bendayan (R)

Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London, London, UK.

Alexandros Papachristidis (A)

King's College Hospital NHS Foundation Trust, London, UK.

James T H Teo (JTH)

King's College Hospital NHS Foundation Trust, London, UK.

Richard J B Dobson (RJB)

Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Health Data Research UK London, Institute of Health Informatics, University College London, London, UK.

Ajay M Shah (AM)

Department of Cardiology, King's College London British Heart Foundation Centre of Research Excellence, School of Cardiovascular Medicine and Sciences, London, UK. ajay.shah@kcl.ac.uk.
King's College Hospital NHS Foundation Trust, London, UK. ajay.shah@kcl.ac.uk.
School of Cardiovascular Medicine and Sciences, James Black Centre, King's College London, 125 Coldharbour Lane, London, SE5 9NU, UK. ajay.shah@kcl.ac.uk.

Rosita Zakeri (R)

Department of Cardiology, King's College London British Heart Foundation Centre of Research Excellence, School of Cardiovascular Medicine and Sciences, London, UK. rosita.zakeri@kcl.ac.uk.
School of Cardiovascular Medicine and Sciences, James Black Centre, King's College London, 125 Coldharbour Lane, London, SE5 9NU, UK. rosita.zakeri@kcl.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH